Technical Analysis for BBIO - BridgeBio Pharma, Inc.

Grade Last Price % Change Price Change
F 23.00 -15.94% -4.36
BBIO closed down 15.94 percent on Monday, June 24, 2024, on 7.22 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Expansion Breakdown Bearish Swing Setup 0.00%
Volume Surge Other 0.00%
Stochastic Reached Oversold Weakness 0.00%
BB Squeeze Ended Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Gapped Down Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Pocket Pivot Bullish Swing Setup -15.94%
Bollinger Band Squeeze Range Contraction -15.94%

   Recent Intraday Alerts

Alert Time
2x Volume Pace about 18 hours ago
1.5x Volume Pace about 18 hours ago
3x Volume Pace about 18 hours ago
10x Volume Pace about 18 hours ago
5x Volume Pace about 18 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

BridgeBio Pharma, Inc. Description

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Clinical Development Protein Kinase Inhibitor Tyrosine Kinase Tyrosine Kinase Receptors Amyloid Amyloidosis Cardiomyopathy Fibroblast Growth Factor Receptor Hyperplasia Myopathy Transthyretin Achondroplasia Congenital Adrenal Hyperplasia Familial Amyloid Polyneuropathy Polyneuropathy TTR Amyloidosis

Is BBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 44.32
52 Week Low 15.36
Average Volume 1,889,553
200-Day Moving Average 30.33
50-Day Moving Average 27.37
20-Day Moving Average 27.58
10-Day Moving Average 27.31
Average True Range 1.64
RSI (14) 31.03
ADX 29.48
+DI 14.86
-DI 34.17
Chandelier Exit (Long, 3 ATRs) 26.51
Chandelier Exit (Short, 3 ATRs) 26.55
Upper Bollinger Bands 30.01
Lower Bollinger Band 25.15
Percent B (%b) -0.44
BandWidth 17.65
MACD Line -0.54
MACD Signal Line -0.18
MACD Histogram -0.3651
Fundamentals Value
Market Cap 4 Billion
Num Shares 174 Million
EPS -3.91
Price-to-Earnings (P/E) Ratio -5.88
Price-to-Sales 636.05
Price-to-Book 123.68
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.65
Resistance 3 (R3) 27.71 26.21 26.88
Resistance 2 (R2) 26.21 25.03 26.19 26.62
Resistance 1 (R1) 24.61 24.30 23.86 24.55 26.36
Pivot Point 23.11 23.11 22.74 23.09 23.11
Support 1 (S1) 21.51 21.93 20.76 21.45 19.64
Support 2 (S2) 20.01 21.20 19.99 19.38
Support 3 (S3) 18.41 20.01 19.13
Support 4 (S4) 18.35